Evidence map›Paper›PMID 42266895›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2026

COPD Patients with a High Exacerbation Risk: Baseline Data Analysis of a National Chinese Prospective Multi-Center Study of Quality Improvement Project.

Kai Yang, Dandan Chen, Yan Wang, Fengyan Wang, Lingwei Wang, Jing Wang, Tingfeng Yu, Huina Hou, Wei Liu, Peirong Huang and 2 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05638646 (A Prospective, Multicentre, Cluster Randomised Controlled Trial to Evaluate the Impact of the Implementation of COPD Quality Standards in High Exacerbation Risk Patients------- A COPD Quality Improvement Program(QIP)), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05638646 naunknown statusnot on this map

A Prospective, Multicentre, Cluster Randomised Controlled Trial to Evaluate the Impact of the Implementation of COPD Quality Standards in High Exacerbation Risk Patients------- A COPD Quality Improvement Program(QIP)

TypeinterventionalSponsorShenzhen People's HospitalRan2022 to 2024Enrolled1,107ConditionsChronic Obstructive Pulmonary DiseaseArmsIntervention group, control group
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kai Yang *Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.ORCID 0000-0002-1982-4398
Dandan Chen *Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.
Yan Wang *Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.
Fengyan WangGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Lingwei WangDepartment of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.
Jing WangDepartment of Respiratory Medicine, People's Hospital of Luxi Yunnan Province, Honghe, People's Republic of China.
Tingfeng YuDepartment of Respiratory and Critical Care Medicine, Yiyang Central Hospital, Yiyang, People's Republic of China.
Huina HouDepartment of Respiratory and Critical Care Medicine, Shangqiu Third People's Hospital, Shangqiu, People's Republic of China.
Wei LiuDepartment of Respiratory and Critical Care Medicine, Luoyang Sixth People's Hospital, Luoyang, People's Republic of China.
Peirong HuangDepartment of Respiratory and Critical Care Medicine, Yuci District People's Hospital, Jinzhong, People's Republic of China.
Hongying YangNational Drug Clinical Trial Institution, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.
Rongchang ChenDepartment of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, People's Republic of China.ORCID 0009-0003-3377-1872

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients with chronic obstructive pulmonary disease (COPD) with a history of frequent exacerbations have a high disease burden and poor progression, demanding optimized management. This study aimed to evaluate the real-world clinical situation, adherence to Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations, and the associated factors. Patients and Methods: We conducted a cross-sectional analysis of baseline data from the national multi-center Quality Improvement Program, which enrolled 1055 COPD patients with a high exacerbation risk from 40 hospitals across five geographic regions in China (NCT05638646). Patient characteristics, disease burden, management patterns and the associated factors were analyzed. Results: The study population had a mean age of 66.2 years, and 85.6% were male. Most patients had substantial disease burden, with 43.3% classified as GOLD stages 3-4 and 93.6% categorized into GOLD group E. In previous 12 months, 39.0% and 67.2% of these patients experienced at least one moderate or severe exacerbation, respectively. Overall, 75.1% received maintenance therapy using long-acting bronchodilators, but only 17.7% were receiving maintenance therapy consistent with the GOLD recommendations for initial treatment. Among patients receiving inhaled therapy, 70.9% initiated maintenance therapy within one month after diagnosis, whereas the self-reported good compliance was only 47.3%. Despite most patients received inhalation technique checks and education, only 61.9% can use the inhalation device appropriately, as evaluated by research team. Hospital level, hospital region, availability of blood eosinophil counts, and disease severity were significantly associated with the management patterns. Conclusion: COPD patients with a high exacerbation risk in China had a substantial disease burden and important gaps between real-world management patterns and GOLD recommendations. These findings suggest opportunities to improve guideline implementation, particularly in secondary and county-based hospitals. Future studies should evaluate whether targeted quality improvement interventions can improve patient outcomes. Trial Registration Number: NCT05638646.

Indexed as

Bronchodilator AgentsLungPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveQuality ImprovementQuality Indicators, Health CareAdministration, InhalationAgedChinaCross-Sectional StudiesDisease ProgressionEast Asian PeopleFemaleGuideline AdherenceHumansMaleBronchodilator Agentschronic obstructive pulmonary diseasedisease burdeninhaled therapy managementnon-pharmacological treatmentpharmacological treatment

Identifiers

PMID42266895
PMCPMC13243137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.